Format

Send to

Choose Destination
Haematologica. 2018 Sep 6. pii: haematol.2018.199844. doi: 10.3324/haematol.2018.199844. [Epub ahead of print]

Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.

Author information

1
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
2
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
3
Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO.
4
The Johns Hopkins University School of Medicine, Baltimore, MD.
5
Memorial Sloan Kettering Cancer Center, New York, NY.
6
National Cancer Institute, Bethesda, MD.
7
John Theurer Cancer Hackensack University Medical Center, Hackensack, NJ.
8
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; hunlee@mdanderson.org.

KEYWORDS:

ABVD; HL; RITUXIMAB

PMID:
30190343
DOI:
10.3324/haematol.2018.199844
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center